<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040415</url>
  </required_header>
  <id_info>
    <org_study_id>DW-1030_301</org_study_id>
    <nct_id>NCT02040415</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase Lll Clinical Trial to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine whether or not DW-1030 is not inferior to
      eperisone HCl in efficacy and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Finger-to-Floor Distance(FFD) compared to baseline 7days after administration</measure>
    <time_frame>1, 3, 7 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of 100mm Pain VAS</measure>
    <time_frame>-3, 1, 3, 7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>1, 3, 7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of using rescue drugs and the total amount</measure>
    <time_frame>1, 3, 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Acute Back Pain</condition>
  <arm_group>
    <arm_group_label>DW-1030(eperisone HCl)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW-1030(eperisone HCl) 75mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myonal Tab.(eperisone HCl)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Myonal Tab.(eperisone HCl) 50mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-1030(eperisone HCl) 75mg</intervention_name>
    <arm_group_label>DW-1030(eperisone HCl)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myonal Tab.(eperisone HCl) 50mg</intervention_name>
    <arm_group_label>Myonal Tab.(eperisone HCl)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drug of DW-1030</intervention_name>
    <arm_group_label>Myonal Tab.(eperisone HCl)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drug of Myonal Tab.</intervention_name>
    <arm_group_label>DW-1030(eperisone HCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males/Females aged over 18 years

          -  Patients with symptom of Acute skeletomuscle myospasm and Back pain

          -  Patients with Pain VAS Value over 40 mm in Visit 2

          -  Subjects who voluntarily or legal guardian agreed with written consent

        Exclusion Criteria:

          -  Patients with Back pain caused by spinal spondylosis, spinal stenosis, fractures,
             cancer, severe arthritis, osteoporosis, sciatica, infection

          -  Muscular patients such as myositis, muscular atrophy disease, increased muscle tone,
             myasthenia gravis

          -  Patients who had taken invasive procedures such as epidural injections or spinal
             stimulation to cure the back pain within 6 months from the screening point

          -  Patients who had taken passive physical therapy or ionphoresis within 12 hours from
             the screening point

          -  Patients with severe GI tract disorder, heart disease, hypertension

          -  Patients who had taken NSAIDS within 24hours from the screening point
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eperisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

